Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M13.3Revenue (TTM) $M17.6Net Margin (%)53.4Altman Z-Score0.1
Enterprise Value $M0.4EPS (TTM) $4.2Operating Margin %53.6Piotroski F-Score8
P/E(ttm)1.5Beneish M-Score--Pre-tax Margin (%)53.4Higher ROA y-yY
Price/Book2.210-y EBITDA Growth Rate %--Quick Ratio2.5Cash flow > EarningsY
Price/Sales0.85-y EBITDA Growth Rate %-23.7Current Ratio2.5Lower Leverage y-yY
Price/Free Cash Flow1.3y-y EBITDA Growth Rate %--ROA % (ttm)227Higher Current Ratio y-yY
Dividend Yield %--PEG--ROE % (ttm)--Less Shares Outstanding y-yY
Payout Ratio %--Shares Outstanding M2.0ROIC % (ttm)--Gross Margin Increase y-yN

Gurus Latest Trades with OPNT

Number of guru portfolios checked: 68.
Ticker Guru Date Action
Impact Price Range
(Average)*
Current Price Change from Average Comment Current Shares

OPNT is held by these investors:



OPNT: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
Sinclair MichaelExecutive Chairman, 10% Owner 2017-01-17Buy3,500$7.01-6.56view
CRYSTAL ROGERCEO, 10% Owner 2017-01-17Buy3,475$6.99-6.29view
Pollack KevinSee Remarks 2017-01-13Buy4,820$6.98-6.16view
Sinclair MichaelExecutive Chairman, 10% Owner 2015-01-15Sell1,700$3.587.14view
Sinclair MichaelExecutive Chairman, 10% Owner 2015-01-15Sell1,700$3.587.14view
COHEN MARC AChairman,CEO,Treas, & Sec, 10% Owner 2012-06-14Sell243$2450-99.73view
KAISER RONALD WDirector 2012-06-06Sell100$2604-99.75view
KAISER RONALD WDirector 2010-12-08Sell100$2608-99.75view
Wesley Melvin IIICFO 2010-11-29Sell11$2424-99.73view
Wesley Melvin IIICFO 2010-11-18Sell23$2190-99.7view

Press Releases about OPNT :

Quarterly/Annual Reports about OPNT:

News about OPNT:

Articles On GuruFocus.com
Opiant Pharmaceuticals, Inc. Announces Results of Positron Emission Tomography (PET) Study of Naloxo Mar 27 2017 
Opiant Pharmaceuticals, Inc. Announces Initiation of Phase 2 Clinical Trial Evaluating OPNT001 in Bu Mar 20 2017 
Companies Aiming for the Billion-Dollar Opioid Addiction Market Mar 18 2017 
Opiant Pharmaceuticals, Inc. Announces FDA Orange Book Listings for Two New NARCAN® Nasal Spray P Mar 09 2017 
Drug Addiction Treatment Stocks to Watch Feb 22 2017 
ANGEL Program Gets National Attention Feb 13 2017 

More From Other Websites
Opiant Pharmaceuticals, Inc. Announces Results of Positron Emission Tomography (PET) Study of... Mar 27 2017
OPNT: Looking to Have a Transformative 2017 Mar 22 2017
Opiant Pharmaceuticals, Inc. :OPNT-US: Earnings Analysis: Q2, 2017 By the Numbers : March 22, 2017 Mar 22 2017
Opiant Pharmaceuticals, Inc. Announces Initiation of Phase 2 Clinical Trial Evaluating OPNT001 in... Mar 20 2017
Opiant Pharmaceuticals, Inc. Reports Fiscal Second Quarter 2017 Financial Results and Provides... Mar 16 2017
Opiant Pharmaceuticals, Inc. Announces FDA Orange Book Listings for Two New NARCAN® Nasal Spray... Mar 09 2017
Opiant Pharmaceuticals, Inc. Receives FDA Feedback Supporting Clinical Development of OPNT002 for... Feb 28 2017
Drug Addiction Treatment Stocks to Watch Feb 22 2017
Opiant Pharmaceuticals, Inc. :OPNT-US: Earnings Analysis: Q1, 2017 By the Numbers : December 20,... Dec 20 2016
OPNT: Receives $13.7M From Monetizing NARCAN® Nasal Spray Royalties Dec 19 2016
Opiant Pharmaceuticals, Inc. :OPNT-US: Earnings Analysis: 2016 By the Numbers : November 22, 2016 Nov 22 2016

Add Notes, Comments

If you want to ask a question or report a bug, please create a support ticket.
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat